I got that from the call as well. Needed more
Post# of 148282
(Total Views: 608)
Posted On: 03/09/2021 1:17:03 AM
I got that from the call as well.
Needed more n, more critical patients, and a representative age distribution between drug and control arms.
Also thought I heard the new trial would be 1 to 1. Wondering if I heard that right and what the secondary endpoints would be.
Nader seems to be relying on Brian Brothen to help fill quickly. My take is the Mr Brothen did make a huge enrollment difference in November and December. Plus there is more data. So they may be able to fill quickly.
So I see some dark weeks coming where people complain about enrollment and worry about dilution. Good time to pick up shares.
Needed more n, more critical patients, and a representative age distribution between drug and control arms.
Also thought I heard the new trial would be 1 to 1. Wondering if I heard that right and what the secondary endpoints would be.
Nader seems to be relying on Brian Brothen to help fill quickly. My take is the Mr Brothen did make a huge enrollment difference in November and December. Plus there is more data. So they may be able to fill quickly.
So I see some dark weeks coming where people complain about enrollment and worry about dilution. Good time to pick up shares.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼